8-K: Establishment Labs Reports Q4 and Full Year 2024 Results, Reaffirms 2025 Guidance

Establishment Labs announces its Q4 and full year 2024 financial results, highlighting U.S. market entry and reaffirming its 2025 revenue guidance.

Summary

• Establishment Labs reported fourth quarter revenue of $44.5 million, consistent with their preannouncement.
• The company's Motiva Implants were approved and launched in the U.S., generating $3.3 million in revenue during the fourth quarter.
• Net loss from operations for the fourth quarter was $18.7 million, a 15% reduction compared to the previous year's $22.1 million loss.
• Adjusted EBITDA loss for the fourth quarter was $13.1 million, a 25% reduction compared to the $17.4 million loss in the same period last year.
• Establishment Labs' cash balance as of December 31, 2024, was $90.3 million, with an additional $25 million available through a credit facility.
• The company reaffirmed its 2025 revenue guidance of $205 million to $210 million, which includes mid-single digit underlying growth in international sales ($170 million to $175 million) and $35 million in U.S. sales.
• First quarter 2025 U.S. revenue is expected to be approximately $5.5 million.
• Preserv was launched in Brazil, expanding the company's minimally invasive portfolio.
• Total revenue for the year ended December 31, 2024, was $166.025 million compared to $165.151 million for the same period in 2023.
• The company is targeting its first positive EBITDA quarter this year and turning cash flow positive next year.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to revenue growth, U.S. market entry, and improved EBITDA loss, but tempered by the ongoing net losses and competitive risks.

Positives

• Motiva Implants received approval and launched in the U.S., contributing $3.3 million in revenue in Q4.
• The company is aggressively managing expenses, leading to an improved EBITDA loss of almost $19 million compared to the previous year.
• Establishment Labs is targeting its first positive EBITDA quarter this year and aims to become cash flow positive next year.
• Cash balance increased $50.3 million from December 31, 2023.
• Gross profit for the fourth quarter was $30.5 million, or 68.5% of revenue, compared to $20.6 million, or 65.2% of revenue, for the same period in 2023.

Negatives

• The company reported a net loss from operations of $18.7 million for the fourth quarter.
• Adjusted EBITDA resulted in a loss of $13.1 million for the fourth quarter.
• Total operating expenses for the fourth quarter were $49.2 million, an increase of $6.5 million compared to the fourth quarter of 2023.

Risks

• The company's future performance is subject to risks and uncertainties related to regulatory approvals, market adoption of products, protection of intellectual property, and economic and competitive factors.
• The company operates in a very competitive and rapidly changing environment, and new risk factors may emerge that could affect business and financial performance.

Future Outlook

Establishment Labs reaffirms its 2025 revenue guidance of $205 million to $210 million and anticipates achieving its first positive EBITDA quarter this year, with the goal of becoming cash flow positive next year.

Management Comments

• The approval of Motiva implants in the United States was a watershed moment for our company, said Juan Jos Chacn-Quirs, Founder and Chief Executive Officer.
• The interest from both plastic surgeons and patients has exceeded our expectations.
• We continue to aggressively manage our expenses, with our EBITDA loss improving almost $19 million this year over last despite the significant step up in our U.S. commercial efforts and investments in our organic innovation pipeline, Mr. Chacn-Quirs continued.
• Our launch into the United States positions us for sustained growth and profitability.
• We are poised to become the global market leader with technologies that can remake and expand the breast aesthetics and reconstruction markets.

Industry Context

Establishment Labs' U.S. market entry with Motiva Implants positions them to compete with established players in the breast implant market, such as Allergan (now AbbVie) and Mentor (Johnson & Johnson). The focus on minimally invasive technologies like Preserv and Mia Femtech aligns with the growing trend towards less invasive cosmetic procedures.

Comparison to Industry Standards

• Establishment Labs' gross margin of 68.5% for Q4 2024 is competitive within the medical device industry.
• Companies like Intuitive Surgical often have gross margins in the 60-70% range.
• However, profitability metrics like EBITDA are still lagging behind industry leaders, as Establishment Labs is still operating at a loss.
• Comparatively, companies like Johnson & Johnson or Medtronic have significantly higher profitability due to their scale and diversified product portfolios.

Stakeholder Impact

• Shareholders can expect continued growth and potential profitability improvements.
• Employees may see opportunities for career advancement as the company expands.
• Customers (patients and surgeons) will have access to new and innovative breast aesthetics and reconstruction options.
• Suppliers may benefit from increased demand for Establishment Labs' products.
• Creditors will be monitoring the company's progress towards profitability and cash flow generation.

Next Steps

• The company plans to continue its U.S. market expansion with Motiva Implants.
• Establishment Labs will focus on expense management to achieve positive EBITDA and cash flow.
• The company will continue to develop and commercialize its minimally invasive technologies.

Key Dates